Board of Directors

Ole Vahlgren

Ole Vahlgren

Chairman of the board

25-years of experience as Senior Pharma Executive, and business development. 

Chairman of the Board

Michael Ulveman

Michael Ulveman

Board Member

Strategic communication specialist, who is advising companies, organizations and top-executives on communication and public affairs. He has worked for two Danish Prime Ministers and the NATO Secretary General on how to set the agenda in the public and navigate in a complex media environment. With +20 years as journalist, correspondent and editor, Michael has a profound insight in local and international media. Postings include Washington DC and Bruxelles. Today he is the Co-founder and partner in Denmarks leading communication agency, Ulveman & Børsting with a staff of 30 employees.  

Board Member

Anders Vadsholt

Anders Vadsholt

Board Member

CFO and advisor of multiple companies including Orphazyme and Minervax 

Board Member

Sebastian Wehle

Sebastian Wehle

Board Member

Sebastian Wehle, a (bio)pharmaceutical executive brings over 20 years of expertise in Manufacturing and Supply, Capital Program Management, and Asset Development. He has a successful track record of launching and supplying one of the first commercial stem cell products, as well as establishing and managing production facilities of various sizes and focus areas. As Chairman on executive-level Program Steering Committees in the past, he has overseen core network expansion strategies, general asset development initiatives, and launch activities.

Board Member

Anella Stelsig Rogaczewski

Anella Stelsig Rogaczewski 

Board Member

Anella Rogaczewski is a successful serial entrepreneur and business advisor. Bachelor business degree from Copenhagen Business School Bachelor of Science (BSc) in Economics and Business Administration, AR has worked in several leading positions in large enterprises within Sales and Marketing, L’Oréal , Burger King, Body shop before  founding and initiating several companies herself. During two decades Anella Rogaczewski founded and/or co-developed several companies in a variety of different industries including Netcompany it consulting, retail physical and online stores, productions of furniture, production and distribution of music rights and a interior design and project management company. Anella Rogaczewski has an education in board leadership from CBS and entered Blue Cell board in 2023. On a voluntary basis Anella Rogaczewski is heavily involved in helping vulnerable children within NGO Red Barnet. 

Board Member

Management Team

Søren P. Sheikh, CEO, MD, PhD

Søren P.Sheikh 

Chief Executive Officer

Plus 35 years of experience in Danish and US Universities and hospitals. Doctoral thesis in gut and neuropeptides and their 7TM receptors. Research activities have mainly focused on stem cell fate and differentiation (adipose derived stem cells and iPS cells and differentiation into cardiomyocytes and endothelial cells), and implementation of stem cell treatment in clinical medicine. In addition, research activities in molecular signaling mechanisms of 7 TM receptors, transcriptome and proteome profiling and use of AI in prostate cancer. Søren established the Danish Centre for Regenerative Medicine at Odense University Hospital (OUH). Søren was head of Dept. of Clinical Biochemistry & Pharmacology at OUH with 280 employees including 35 scientists for 15 years. Søren established and served as head of the Center for Vascular Regeneration at OUH/SDU, a center that implements stem cell treatments in clinical practice. Søren is and has been member of several editorial boards and other scientific advisory boards including the Research Council for Southern Denmark. Søren is a co-founder and CEO of Blue Cell Therapeutics, consisting of 14 employees.  

Chief Executive Officer

Jakob Lerche Hansen, CSO, MSc, PhD

Jakob Lerche Hansen

Cheif Scientific Officer

 
Plus 25 years from Industry and academia as a scientist and leader. 10 years’ experience at Novo Nordisk to deliver and develop ideas for new drugs, biological understanding and in-vitro assays into the project-pipeline and focus groups. Core contributor to the Novo Nordisk AM833 (cagrilintide) program, that has yielded very strong results in phase II clinical trials for the treatment of obesity. Detailed experience as scientific scout, evaluator, and anchor on multiple external collaborations with academia and biotech. Specialist in in-vitro pharmacology and assay development for analogue screening, characterization, and evaluation biological mode of action. 7TM Receptor pharmacology and signal transduction with focus on understanding of the receptor and ligand interaction and biology, with the aim of drug development within Obesity, Diabetes, and Cardiovascular disease.

Chief Scientific Officer

Gitte Lund Christensen, Research Director, MSc, PhD

Gitte L. Christensen

Director

Gitte has more than 20 years of experience within cell biology, assay development and research management. She has extensive experience with primary cells and substantial research experience from several areas, including cardiology, diabetes, cancer and osteoporosis.  Gitte contributes with deep knowledge in research and development and experience with strategy and project development from positions at University of Copenhagen and Copenhagen University hospital.  

Gitte is educated as a Cell biologist from University of Copenhagen and holds a PhD in medical Sciences from University of Copenhagen. 

 

Director

Thomas Sandal, CDO

Thomas Sandal

Chief Data Officer

Thomas is a biotech leader with 30+ years of experience within the Biotech and Biopharmaceutical industry. He has been responsible for early-stage discovery and CMC development of antibodies and antibody fragments within indications such as RA (Sub cutaneous delivered), ALI (pulmonary delivered), Psoriasis (topical delivered), oncology (CPI’s, ADC’s and autologous T cell therapy) and Microbiome bacterial consortia products. Thomas brings deep insight to biotech company building, R&D strategy, planning, implementation and prioritization from his executive and senior positions at PokeAcell, AGC Biologics, Microbiotica Ltd, Crescendo Biologics Ltd, GSK, Ltd. and Domantis. In these positions Thomas has progressed several compounds to clinical stages. Thomas graduated as a molecular biologist and holds a degree in engineering from the Technical University of Denmark and a Business Administration degree from Copenhagen University College of Engineering.

Chief Developer Officer

Team

Mette Søgaard Hansen

Senior Laboratory Technician

Cell biology & assay development

Marie-Louise Krogh


Senior Project Manager

Benjamin Claass

Senior Scientist

Research & CMC

Martha Seikh Chahid


Administrative Project Manager

Katrine Mark


Laboratory Manager

Elena Pedraz Cuesta

Senior Scientist

Research & Project Manager

MingShu Meng Eriksen

Senior Laboratory Technician

Cell biology & assay development

Maja Lind Nybo

Senior Scientist

In vivo biology & toxicology

Jone Marita Kvam

Research Scientist

In vivo biology

Visnja Radulovic

Senior Scientist

In vitro biology

Christoffer Valgreen

Student Assistant

Finance

Javier Ruiz Gonzalez

Student Assistant

Marketing

Advisory Board

Miguel Mullet

Advisory Board Member

Klaus Brasso

Klaus Brasso

Advisory Board Member

Klaus Brasso is a MD., PhD., senior consultant urologists and former professor at the Department of Urology, Rigshospitalet, University of Copenhagen Denmark. His primary focus area is prostate cancer, being involved in all aspects of managing men with prostate cancer, being involved in studies ranging from basic epidemiology to clinical trials in men with advanced disease. Klaus Brasso has been serving as a Danish representative in the Scandinavian Prostate Cancer Group.

Advisory Board Member